One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses
| Autor: | Tanja Schjødt Jørgensen, Lennart T H Jacobsson, Ulf Lindström, Dan Nordström, Johan Askling, Anna-Mari Hokkanen, Johan K. Wallman, Sella Aarrestad Provan, Brigitte Michelsen, Kalle Aaltonen, Arni Jon Geirsson, Bente Glintborg, Merete Lund Hetland, Artis Danbio (Denmark), Rebekka Lund Hansen, Lars Erik Kristensen, Srq registries, Kathrine Lederballe Grøn, Niels Steen Krogh, Daniela Di Giuseppe, Bjorn Gudbjornsson |
|---|---|
| Přispěvatelé: | HUS Internal Medicine and Rehabilitation, Helsinki University Hospital Area, Department of Medicine, Clinicum |
| Rok vydání: | 2020 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty Antibodies Monoclonal Humanized Inflammatory bowel disease 03 medical and health sciences 0302 clinical medicine Rheumatology Psoriasis Internal medicine INFLIXIMAB Spondylarthritis Adalimumab ETANERCEPT Medicine Humans Spondylitis Ankylosing Prospective Studies Registries Prospective cohort study 030203 arthritis & rheumatology Ankylosing spondylitis Biological Products PSORIASIS business.industry Hazard ratio ANKYLOSING-SPONDYLITIS medicine.disease EFFICACY 3. Good health Discontinuation RHEUMATOID-ARTHRITIS Treatment Outcome 3121 General medicine internal medicine and other clinical medicine Secukinumab AXIAL SPONDYLOARTHRITIS Tumor Necrosis Factor Inhibitors business medicine.drug |
| Zdroj: | Danish Rheumatology Database (DANBIO), Anti-RheumaticTherapy in Sweden/Swedish Rheumatology Quality (ARTIS/SRQ), Center for Rheumatology Research (ICEBIO), Finnish Register of Biological Treatment (ROB-FIN) & Norwegian Antirheumatic Drug Register (NOR-DMARD) 2022, ' One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis : Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses ', Arthritis Care and Research, vol. 74, no. 5, pp. 748-758 . https://doi.org/10.1002/acr.24523 |
| ISSN: | 2151-4658 |
| DOI: | 10.1002/acr.24523 |
| Popis: | Objective: To describe baseline characteristics and to compare treatment effectiveness of secukinumab versus tumor necrosis factor inhibitors (TNFi) in patients with spondyloarthritis (SpA) using adalimumab as the main comparator. Methods: This was an observational, prospective cohort study. Patients with SpA (clinical ankylosing spondylitis, nonradiographic axial SpA, or undifferentiated SpA) starting secukinumab or a TNFi during 2015–2018 were identified from 5 Nordic clinical rheumatology registries. Data on comorbidities and extraarticular manifestations (psoriasis, uveitis, and inflammatory bowel disease) were captured from national registries (data available in 94% of patients) and included in multivariable analyses. We assessed 1-year treatment retention (crude survival curves, adjusted hazard ratios [HRadj] for treatment discontinuation) and 6-month response rates (Ankylosing Spondylitis Disease Activity Score [ASDAS] score adj 1.43 [95% CI 1.12–1.81]). Across treatment lines, secukinumab had poorer estimates for 6-month response rates than adalimumab, statistically significantly only for the third-plus line (adjusted analyses: ASDAS score |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text